The Chemotherapy-Induced Anemia Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Chemotherapy-Induced Anemia Market:
According to The Business Research Company’s Chemotherapy-Induced Anemia Global Market Report 2024, The chemotherapy-induced anemia market size has grown strongly in recent years. It will grow from $2.4 billion in 2023 to $2.6 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increased prevalence of cancer and chemotherapy treatments, aging population leading to higher cancer incidence, expansion of chemotherapy drugs and regimens, improvement in overall cancer survival rates, awareness and diagnosis of anemia as a side effect
The chemotherapy-induced anemia market size is expected to see strong growth in the next few years. It will grow to $3.46 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to development of supportive care in oncology, rise in healthcare expenditure and infrastructure, personalized medicine and targeted cancer therapies, integration of biomarker-driven treatment approaches, increasing focus on early detection and intervention, integration of digital health technologies in patient management. Major trends in the forecast period include innovation of novel chemotherapy agents, integration of ml, advancements in cancer research and treatment protocols, integration of ai, collaboration between pharmaceutical companies and healthcare providers.
The high prevalence of cancer and anemia is expected to propel the growth of the chemotherapy-induced anemia market going forward. Cancer is a disease where somebody’s cells grow out of control and spread to other body regions. In cancer patients receiving aggressive chemotherapy, whether with or without radiation therapy, cancer and chemotherapy-induced anemia (CIA) are frequent occurrences. The medication stimulates the production of red blood cells in the bone marrow and can be used to treat chemotherapy-induced anemia. For instance, in 2023, according to Cancer Research UK, a UK-based independent cancer research organization, the incidence of head and neck cancer in the UK is projected to rise by 3% between 2023 and 2025, while deaths due to head and neck cancers are expected to increase by 12% between 2023 and 2025. Therefore, the high prevalence of cancer and anemia drives the growth of the chemotherapy-induced anemia market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=11967&type=smp
The chemotherapy-induced anemia market covered in this report is segmented –
1) By Anemia: Mild Anemia, Moderate Anemia, Severe Anemia, Life-Threatening Anemia
2) By Treatment Type: RBC (Red Blood Cells) Transfusion, Erythropoiesis-Stimulating Agents (ESAs), Iron Supplementation
3) By End-User: Hospitals, Ambulatory Surgical Centers, Multispecialty Clinics, Cancer Research Centers,Cancer Rehabilitation Centers
Major companies in the chemotherapy-induced anemia market are focused on developing innovative therapy, such as myeloprotection therapy, for extensive-stage small cell lung cancer and to gain a competitive edge in the market. Myeloprotection therapy is a medical approach aimed at safeguarding bone marrow from damage caused by chemotherapy, reducing associated complications. For instance, in February 2021, G1 Therapeutics Inc., a US-based biopharmaceutical company, received FDA approval for COSELA (trilaciclib), the first myeloprotection therapy designed to reduce chemotherapy-induced myelosuppression, a condition characterized by a reduction in blood cell production in the bone marrow, and it can lead to complications such as neutropenia, anemia, and thrombocytopenia in patients with extensive-stage small-cell lung cancer. Administered before chemotherapy, COSELA protects bone marrow, reducing severe neutropenia incidence and duration. It offers multilineage protection, impacting anemia and the need for rescue interventions.
The chemotherapy-induced anemia market report table of contents includes:
1. Executive Summary
2. Chemotherapy Induced Peripheral Neuropathy Treatment Market Characteristics
3. Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends And Strategies
4. Chemotherapy Induced Peripheral Neuropathy Treatment Market – Macro Economic Scenario
5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Growth
.
.
.
26. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market
27. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market
28. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market
29. Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market
30. Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Landscape And Company Profiles
Top Major Players:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Bidirectional Electric Vehicle Charger Market, 2024 report by The Business Research Company offers comprehensive insights…
Market Size - The hazelnut market size has grown strongly in recent years. It will…
Market Size - The IoT gateway devices market size has grown rapidly in recent years.…
The industrial automation cable market size is expected to see strong growth in the next…
Market Size - The zinc rich coating market size has grown rapidly in recent years.…
The fleet management software market size is expected to see rapid growth in the next…